摘要
目的观察鼻窦内镜术(ESS)对慢性鼻窦炎伴支气管哮喘患者的疗效。方法对100例行ESS术患者分为慢性鼻窦炎伴支气管哮喘(A组)50例和慢性鼻窦炎(B组)50例,于行ESS术前、术后采用酶联免疫吸附测定法(ELISA)检测白细胞介素4(IL-4)、干扰素γ(IFN-γ)、可溶性白细胞介素-2受体(sIL-2R)和可溶性IgE低亲和力受体(sCD23)的含量,并与20例正常对照组进行比较。结果A组患者治疗前IL-4、sCD23含量分别为(93±47)ng/L、(1.83±0.62)ng/L,sIL-2R含量为(720±167)μg/L;B组患者治疗前IL-4、sCD23含量分别为(84±40)ng/L、(1.72±0.48)ng/L-1,sIL-2R含量为(649±146)μg/L,均明显高于对照组[(41±25)ng/L、(1.10±0.22)ng/L,(367±123)μg/L];治疗后A组IL-4、sCD23、sIL-2R含量[(60±30)ng/L、(1.11±0.38)ng/L、(540±151)μg/L]低于治疗前;治疗后IFN-γ含量(410±241)μg/L高于治疗前(311±240)μg/L;A组术后哮喘改善水平由随访术后1年的60%提高到术后2年的80%。结论ESS对慢性鼻窦炎伴支气管哮喘患者的治疗有较满意的远期疗效。
Objective To observe the effect of endoscopic sinus surgery（ESS） in chronic sinusitis and polyps with asthma. Methods 100 patients were divided into two groups. All patients in A group with chronic sinusitis and polyps with asthma and those in B group with chronic sinusitis and polyps were treated by ESS. The contents of interleukin-4（IL-4） ,interferon-7 （IFN-7） , soluble interieukin 2-receptor （sIL2-R） and soluble CD23 （ sCD23 ） levels were determined after treatment and before treatment by enzyme-linked immunosorbent assay（ELISA）. Results The contents of IL-4, sCD23 and slL-2R in A group before treatment were （93 ± 47 ） ng/L, （ 1.83 ± 0.62 ） ng/L, （720 ± 167）μg/L;The contents of IL-4 ,sCD23 and sIL-2R in B group were （84 ± 40）ng/L, （1.72 -± 0.48）ng/L. （649 ± 146）μg/L;Obviously higher than that in control group[ （41 ± 25 ） ng/L, （1.10 ± 0.22） ng/L, （367 ± 123） μg/L]. The contents of IL-4 ,sIL-2R and sCD23 after treatment were[ （60 ± 30）ng/L, （1.11 ± 0.38）ng/L, （540 ± 151） μg/L] obviously lower than that before treatment;The contents of IFN-7 after treatment were （410 ± 241 ）μg/ L obviously higher than that before treatment （311 ±240）μg/L;The asthma improved in A group with the 60 % of a year increasing 80% of 2 years. Conclusion ESS has a favorable effect on asthma in patients with symptomatic chronic sinusitis.
出处
《中国基层医药》
CAS
2006年第10期1625-1627,共3页
Chinese Journal of Primary Medicine and Pharmacy
